These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27545047)

  • 1. Reduced occurrence of severe visual impairment after introduction of anti-Vascular Endothelial Growth Factor in wet age-related macular degeneration - a population- and register-based study from northern Sweden.
    Granstam E; Westborg I; Barkander A; Börjesson M; Lindahl S; Meszaros E; Wojciechowska-Zajac A; Wagner P; Albrecht S; Karlsson N; Bjärnhall G; Lövestam-Adrian M
    Acta Ophthalmol; 2016 Nov; 94(7):646-651. PubMed ID: 27545047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.
    Westborg I; Granstam E; Rosso A; Albrecht S; Karlsson N; Lövestam-Adrian M
    Acta Ophthalmol; 2017 Dec; 95(8):787-795. PubMed ID: 28834299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RISK FOR LOW VISUAL ACUITY AFTER 1 AND 2 YEARS OF TREATMENT WITH RANIBIZUMAB OR BEVACIZUMAB FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Westborg I; Albrecht S; Rosso A
    Retina; 2017 Nov; 37(11):2035-2046. PubMed ID: 28141748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration.
    Campbell JP; Bressler SB; Bressler NM
    Arch Ophthalmol; 2012 Jun; 130(6):794-5. PubMed ID: 22801846
    [No Abstract]   [Full Text] [Related]  

  • 5. VITREOMACULAR TRACTION AFFECTS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OUTCOMES FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION.
    Krishnan R; Arora R; De Salvo G; Stinghe A; Severn PS; Pal B; Goverdhan S
    Retina; 2015 Sep; 35(9):1750-6. PubMed ID: 26237240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom.
    Buckle M; Lee A; Mohamed Q; Fletcher E; Sallam A; Healy R; Stratton I; Tufail A; Johnston RL
    Eye (Lond); 2015 Mar; 29(3):403-8. PubMed ID: 25592123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration.
    Finger RP; Guymer RH; Gillies MC; Keeffe JE
    Ophthalmology; 2014 Jun; 121(6):1246-51. PubMed ID: 24518613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
    Gillies MC; Campain A; Barthelmes D; Simpson JM; Arnold JJ; Guymer RH; McAllister IL; Essex RW; Morlet N; Hunyor AP;
    Ophthalmology; 2015 Sep; 122(9):1837-45. PubMed ID: 26096346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in eyes receiving fixed-interval dosing of anti-vascular endothelial growth factor agents for wet age-related macular degeneration.
    Peden MC; Suñer IJ; Hammer ME; Grizzard WS
    Ophthalmology; 2015 Apr; 122(4):803-8. PubMed ID: 25596618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision.
    Toth LA; Stevenson M; Chakravarthy U
    Retina; 2015 Oct; 35(10):1957-63. PubMed ID: 25946692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
    Arnold JJ; Campain A; Barthelmes D; Simpson JM; Guymer RH; Hunyor AP; McAllister IL; Essex RW; Morlet N; Gillies MC;
    Ophthalmology; 2015 Jun; 122(6):1212-9. PubMed ID: 25846847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.
    Abedi F; Wickremasinghe S; Richardson AJ; Makalic E; Schmidt DF; Sandhu SS; Baird PN; Guymer RH
    Ophthalmology; 2013 Jan; 120(1):115-21. PubMed ID: 23149126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of outcomes from a phase 3 study of age-related macular degeneration with a matched, observational cohort.
    Gillies MC; Walton RJ; Arnold JJ; McAllister IL; Simpson JM; Hunyor AP; Guymer R; Essex RW; Morlet N; Barthelmes D
    Ophthalmology; 2014 Mar; 121(3):676-81. PubMed ID: 24290801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of vascular endothelial growth factor polymorphisms in the treatment success in patients with wet age-related macular degeneration.
    Boltz A; Ruiß M; Jonas JB; Tao Y; Rensch F; Weger M; Garhöfer G; Frantal S; El-Shabrawi Y; Schmetterer L
    Ophthalmology; 2012 Aug; 119(8):1615-20. PubMed ID: 22521084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TREATMENT OUTCOMES FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION PATIENTS WITH INITIAL VISION BETTER THAN 20/40 USING A TREAT-AND-EXTEND REGIMEN.
    Rahimy E; Rayess N; Ho AC; Regillo CD
    Retina; 2016 May; 36(5):875-80. PubMed ID: 26630316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy.
    Tabandeh H; Chaudhry NA; Boyer DS; Kon-Jara VA; Flynn HW
    J Cataract Refract Surg; 2012 Apr; 38(4):677-82. PubMed ID: 22284725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Best-corrected visual acuity and retinal thickness are associated with improved cortical visual processing in treated wet AMD patients.
    Vottonen P; Pääkkönen A; Tarkka IM; Kaarniranta K
    Acta Ophthalmol; 2015 Nov; 93(7):621-5. PubMed ID: 26031317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-VEGF response in macular hemorrhage and incidence of retinal pigment epithelial tears.
    Varshney N; Jain A; Chan V; Yu L; Sarraf D
    Can J Ophthalmol; 2013 Jun; 48(3):210-5. PubMed ID: 23769784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.